Repatha SureClick

  • Name:

    Repatha SureClick

  • Company:
    info
  • Active Ingredients:

    Evolocumab

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 27/02/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 27/2/2020
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

Amgen Ltd

Amgen Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name AMGEVITA prefilled pen Active Ingredients adalimumab
Medicine Name AMGEVITA prefilled syringe Active Ingredients adalimumab
Medicine Name Aranesp PFS Active Ingredients Darbepoetin alfa
Medicine Name ARANESP PFS with needle guard Active Ingredients Darbepoetin alfa
Medicine Name Aranesp SureClick Active Ingredients Darbepoetin alfa
Medicine Name Blincyto Active Ingredients Blinatumomab
Medicine Name Imlygic Active Ingredients Talimogene laherparepvec
Medicine Name KANJINTI Active Ingredients Trastuzumab
Medicine Name Kyprolis Active Ingredients Carfilzomib
Medicine Name Mimpara Granules Active Ingredients cinacalcet hydrochloride
Medicine Name Mimpara tablets Active Ingredients cinacalcet hydrochloride
Medicine Name Neulasta On Body Injector Active Ingredients Pegfilgrastim
Medicine Name Neulasta Pre-Filled Syringe Active Ingredients Pegfilgrastim
Medicine Name Neupogen 30 MU (0.3 mg/ml) solution for injection Active Ingredients Filgrastim
Medicine Name Neupogen Singleject 30 MU (0.6 mg/ml) Active Ingredients Filgrastim
Medicine Name Neupogen Singleject 48 MU (0.96 mg/ml) Active Ingredients Filgrastim
Medicine Name Nplate Active Ingredients Romiplostim
Medicine Name Nplate reconstitution kit Active Ingredients Romiplostim
Medicine Name Otezla 10mg, 20mg, 30mg Active Ingredients Apremilast
Medicine Name Parsabiv Active Ingredients etelcalcetide
Medicine Name Prolia Active Ingredients Denosumab
Medicine Name Repatha SureClick Active Ingredients Evolocumab
Medicine Name Vectibix Active Ingredients Panitumumab
Medicine Name XGEVA Active Ingredients Denosumab
1 - 0 of 24 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 27 February 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Section 2. What you need to know before you use Repatha

Talk to your doctor, pharmacist or nurse before using Repatha if you have:

  • liver disease.,
  • severe kidney problems.
     
    Date of revision of the text
    November 2019 January 2020

Updated on 27 February 2020 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Deleted text with strikethrough, new text in bold

 

Section 4.2 Posology and method of administration

Patients with renal impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment (see section 5.2)., see section 4.4 for patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2).

 

Section 4.4 Special Warnings and Precautions

Renal impairment

There is limited experience with Repatha in patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) (see section 5.2). Repatha should be used with caution in patients with severe renal impairment.

 

5.2 Pharmacokinetic properties

Renal impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment. Population pharmacokinetic analysis of integrated dData from the Repatha clinical trials did not reveal a difference in pharmacokinetics of evolocumab in patients with mild or moderate renal impairment relative to non-renally impaired patients. There is limited experience with Repatha in patients with severe renal impairment (see section 4.4).

In a clinical trial of 18 patients with either normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 mL/min/1.73 m2, n = 6), severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2, n = 6), or end-stage renal disease (ESRD) receiving haemodialysis (n = 6), exposure to unbound evolocumab as assessed by Cmax after a single 140 mg subcutaneous dose was decreased by 30% in patients with severe renal impairment and by 45% in patients with ESRD receiving haemodialysis.  Exposure as assessed by AUClast was decreased by approximately 24% in patients with severe renal impairment and by approximately 45% in patients with ESRD receiving haemodialysis. The exact mechanism of PK differences is unknown; however, differences in body weight could not explain these differences. Some factors including small sample size and large inter-subject variability should be considered when interpreting the results.  The pharmacodynamics and safety of evolocumab in patients with severe renal impairment and ESRD were similar to patients with normal renal function, and there were no clinically meaningful differences in LDL-C lowering.  Therefore, no dose adjustments are necessary in patients with severe renal impairment or ESRD receiving haemodialysis.

 

Section 10 Date of revision of the text

November 2019 January 2020

Updated on 27 November 2019 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects - Addition of hypersensitivity as a common Adverse Event

Section 10 Date of revision of the text - Updated to November 2019

Updated on 27 November 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Section 4 Side Effects - Updated to state “Allergic reactions including rash” as a common side effect

Date of revision of the text - Updated to November 2019

Updated on 16 October 2019 PIL

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to date of revision

Free text change information supplied by the pharmaceutical company

Section 2 What you need to know before you use Repatha

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.i.e. it is essentially ‘sodium- free’ and should not affect a sodium-controlled diet.

Section 4 Side Effects

Flu like symptoms

Date of revision of the text

September 2019

Updated on 16 October 2019 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

Additon of Influenza-like illness as an uncommon adverse reaction

Section 10 Date of revision of teh text

September 2019

Updated on 14 August 2019 SmPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 5.1 Pharmacodynamic properties - update to information relating to the OSLER trials

Section 10 Date of revision of the text - July 2019

Updated on 24 July 2019 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

5.1     Pharmacodynamic properties

Information relating to the TAUSSIG trial has been updated.

Information in Tables 5 and 7 relating to the TAUSSIG trial has been updated.

 

10.     DATE OF REVISION OF THE TEXT

 Date of revision has been updated to June 2019

Updated on 9 May 2019 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Change to improve clarity and readability

Updated on 7 May 2019 PIL

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Change to improve clarity and readability

Updated on 7 May 2019 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

 

Tabulated summary of adverse reactions

Adverse reactions reported in pivotal, controlled clinical studies, and spontaneous reporting, are displayed by system organ class and frequency in table 1 below using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).

 

Table 1. Adverse reactions with Repatha

  • Addition of angioedema as a rare adverse reaction

 

Section 10 Date of revision of the text

April 2019

Updated on 3 August 2018

Updated on 29 May 2018 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 29 May 2018 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of new indication "Established atherosclerotic cardiovascular disease" and subsequently changes made to sections 4.2, 5.1 and 5.2

Changes to section 4.4 regarding patients with renal impairment

Changes to section 4.8 injection site reactions

Updated on 21 May 2018 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1 Therapeutic indications

Addition of new indication Established atherosclerotic cardiovascular disease

 4.2 Posology and method of administration

Update to the posology sub-section with information on Established atherosclerotic cardiovascular disease in adults

4.4 Special Warnings and Precautions

Update to the renal impairment sub-section

4.8 Undesirable Effects

Update to the Summary of the safety profile, Injection site reactions, Elderly population and Immunogenicity sub-sections

5.1 Pharmacodynamic properties

Update to the Clinical efficacy in primary hypercholesterolaemia and mixed dyslipidaemia sub-section

 

New information - Effect on atherosclerotic disease burden & Cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease

Section 5.2 Pharmacokinetic properties

Update to sub section renal impairment

10 Date of revision of the text

May 2018

Updated on 18 May 2018 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 11 March 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 March 2018 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

The shelf life of the Repatha® pre-filled syringe and the Repatha® pre-filled pen (SureClick®) has been extended to 3 years. 

Please note that the Repatha® pre-filled syringe is not marketed in Ireland


Section 6.3 Shelf life

Repatha 140 mg solution for injection in pre-filled syringe
3 years.

Repatha 140 mg solution for injection in pre-filled pen
3 years.

Repatha 420 mg solution for injection in cartridge
2 years.

Section 10. DATE OF REVISION OF THE TEXT

Updated to March 2018

Updated on 11 April 2017 PIL

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 11 April 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 24 February 2017 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change from individual to joint SPC

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



 

The Repatha Summary of Product Characteristics has been updated to now incorporate three presentations:

 

1)         Solution for injection in pre-filled syringe

2)         Solution for injection in pre-filled pen (SureClick)

3)         Solution for injection in cartridge (automated mini-doser)

 

Please note that the Repatha solution for injection in pre-filled syringe and cartridge (automated mini-doser) are not available in Ireland.

Updated on 24 February 2017 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 30 September 2016 PIL

Reasons for updating

  • Change to storage instructions
  • Change to date of revision

Updated on 30 September 2016 SmPC

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following sections of the SmPC have been updated:

 

Section 6.4 Special precautions for storage:

 

Previous text:

If removed from the refrigerator, Repatha may be stored at room temperature (up to 25°C) in the original carton and must be used within 1 week.

 

New text:

If removed from the refrigerator, Repatha may be stored at room temperature (up to 25°C) in the original carton and must be used within 1 month.

 

 

10.    DATE OF REVISION OF THE TEXT

Previous text:

July 2015

 

New text:

September 2016

Updated on 29 June 2016 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 31 July 2015 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 31 July 2015 PIL

Reasons for updating

  • New PIL for new product